


2022 Guidelines: Pharmacologic Management Algorithm As of November 2022

American Diabetes Association/European Association for the Study of Diabetes recommendations for the treatment of hyperglycemia in people with diabetes



^{*}If adequate eGFR, [^]Empagliflozin/dapagliflozin have shown benefit in dedicated HF studies. Canagliflozin/ertugliflozin demonstrated reduction in hospitalization for HF in cardiovascular outcomes trials. [#]Dapagliflozin/canagliflozin/empagliflozin demonstrated benefit in dedicated renal studies.

^{*}start if eGFR >20 mL/min/1.73 m², continue until HD or transplant.

DSMES=diabetes self-management education and support, SDOH=social determinants of health, ASCVD=atherosclerotic cardiovascular disease, HFrEF=heart failure with reduced ejection fraction, HFpEF=heart failure with preserved ejection fraction, CV=cardiovascular, CKD=chronic kidney disease, GLP-1 RA=glucagon-like peptide-1 receptor agonist, SGLT2i=sodium-glucose cotransporter-2 inhibitor, TZD=thiazolidinedione, SFU=sulfonylurea, MTF=metformin.

Reference
 Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi: 10.2337/dci22-0034.

The Ohio Cardiovascular and Diabetes Health Collaborative is funded by the Ohio Department of Medicaid and administered by the Ohio Colleges of Medicine Government Resource Center. The views expressed in this document are solely those of the authors and do not represent the views of the state of Ohio or federal Medicaid programs. © 2023 Cardi-OH